Share this article

Mallinckrodt has agreed to fund a clinical trial conducted by US researchers to assess the use of its inhaled nitric oxide therapy, INOmax, to treat lung complications in Covid-19 patients.

The company would offer funding support, as well as INOmax, for the investigator-initiated trial at Massachusetts General Hospital.

The primary objective of the study is the potential efficacy of inhaled nitric oxide in reversing abnormally low oxygen levels in the blood of Covid-19 patients with severe lung complications.

Read the full article here

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData